偏头痛患者的治疗模式符合抗CGRP通路单克隆抗体的条件
Ani C Khodavirdi1, Jasjit K Multani2, Sam S Oh1
1Amgen Inc., Thousand Oaks, CA, United States.
Frontiers in neurology
|August 21, 2024
概括
这项研究分析了美国偏头痛治疗模式. 抗CGRP通路单克隆抗体 (mAbs) 在非慢性偏头痛患者中使用率较低,尽管急性药物使用量很高,这表明存在未满足的需求.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 医疗保健服务研究 医疗服务研究
背景情况:
- 偏头痛是一种异质的神经系统疾病,对患者造成重大负担.
- 了解治疗模式对于优化护理至关重要,特别是在预防性治疗中,如抗CGRP通路单克隆抗体 (mAbs).
- 需要真实世界的数据来评估急性和预防性偏头痛药物的使用.
研究的目的:
- 分析美国偏头痛患者的情况,这些患者有资格接受抗CGRP通路mAb的预防性治疗.
- 了解真实世界的治疗模式和偏头痛患者的药物使用.
- 确定对急性药物治疗需求较高的患者的护理方面的潜在缺口.
主要方法:
- 使用IQVIA PharMetrics® Plus数据库进行的回顾性队列研究.
- 使用诊断码或药物使用识别了成年患有偏头痛的患者.
- 分层患者为慢性偏头痛 (CM) 和非慢性偏头痛 (非CM) 组;非CM患者进一步按急性药物使用分类.
主要成果:
- 包括22584名CM患者和216807名非CM患者.
- 冠状病毒患者平均使用70单位急性药物;最高三位数的非冠状病毒患者使用92单位.
- 抗CGRP路径mAbs被分发给了28.9%的CM患者,而6.9% (最高三位非CM),4.1% (中位) 和2.9% (最低).
结论:
- 与CM患者相比,非CM患者使用抗CGRP通路mAbs的比例较低,这凸显了预防性治疗的未满足需求.
- 在管理经常使用急性偏头痛药物的非CM患者方面存在重大差距.
- 需要进一步的研究,以解决在特定患者群体中偏头痛治疗不足的问题.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
01:20Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
01:22Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171
01:27Open Angle Glaucoma: Treatment
413
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
413
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
149
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
149